Marksans Pharma delivers record Q1FY27 Results; Profitability jumps as cash balance crosses ₹1,000 crore

Marksans Pharma delivers record Q1FY27 Results; Profitability jumps as cash balance crosses ₹1,000 crore​

Mumbai: Marksans Pharma Ltd reported strong financial results for the quarter ended June 30, 2026, highlighting all-time high profitability. The company saw its EBITDA rise 112.8% year-on-year (YoY) to ₹213 crore, while PAT grew by 173.9% YoY to ₹159 crore. A key achievement was the company crossing a cash balance of ₹1,000 crore for the first time, closing the quarter at ₹1,058 crore, despite recent acquisitions of QliniQ and ABCnow.

Mark Saldanha, Managing Director of Marksans Pharma, stated that Q1FY27 represented a strong start to the year, reflecting the underlying business strength and continued focus on profitable growth.

"UK and Europe delivered their highest ever quarterly revenue of ₹356 crore, growing at 74.7% YoY," Saldanha said. "Europe is emerging as a significant new growth engine for the Group with the acquisition of QliniQ and the establishment of our front-end presence across the region. We also crossed ₹1,000 crore in cash balance for the first time, providing us with the financial strength and flexibility to continue investing in organic growth while pursuing calibrated inorganic opportunities."

The company plans to carry this momentum forward by scaling businesses across geographies, accelerating new launches, and further strengthening its European platform.

Q1FY27 Financial Highlights​

Marksans Pharma reported robust performance across several key metrics:

• Operating Revenue stood at Rs. 840 cr., marking a 35.6% increase YoY.
• Gross profit reached Rs. 497 cr., up 38.9% YoY, achieving a gross margin of 59.1%.
• EBITDA reached Rs. 213 cr., a 112.8% jump YoY, with an EBITDA margin of 25.3%.
• PAT stood at Rs. 159 cr., up 173.9% YoY, resulting in a net margin of 18.4%.
• Earnings Per Share (EPS) was reported at Rs. 3.5.

Business Segment Performance Analysis​

The company’s operations spanned several markets, demonstrating diverse growth trends:


The UK and Europe market reported Rs. 356 cr. in revenue, achieving the highest ever quarterly revenue for this region and growing at 74.7% YoY. The expansion into the European Union (EU) commenced ahead of the Q2FY27 timeline, with QliniQ B.V. (Netherlands) contributing Rs. 44 crore in Q1FY27.

The US & North America Formulation business generated revenues of Rs. 377 cr., showing a 15.1% YoY increase and contributing approximately 45% of consolidated revenue. Meanwhile, the Australia and New Zealand market reported Rs. 87.6 cr., an increase of 53.7% YoY. The Rest of World (ROW) business recorded revenues of Rs. 20 cr., a decline of 36.8% YoY, yet marked the first sequential improvement in four quarters, up 6.0% Quarter-on-Quarter (QoQ).

Consolidated Financial Performance Overview​

The company’s consolidated profit and loss statement highlights significant margin expansion:


All figures are in Rs. Cr. unless otherwise noted.

Other Operational Highlights​

During Q1FY27, the company generated ₹185 cr in cash from operations and incurred a Net Capex of ₹33 cr, resulting in a free cash flow of ₹152 cr. The working capital cycle stood at approximately 132 days, an improvement from around 159 days in Q1FY26.

The company completed the acquisition of 100% of QliniQ B.V and ABCnow in Europe. Furthermore, Fitch Group revised the outlook on the Company's bank loan facilities to Positive from Stable, while affirming ratings at IND AA-/IND A1+.

Investor Conference Call​

An Earnings conference call is scheduled for August 13, 2026, at 4:30 pm IST, where the leadership team will discuss the financial performance and take questions.

MARKSANS Stock Price Movement​

Shares of Marksans Pharma Limited are edging higher to ₹315.75 as of 3:25 PM, surging by 13.19% in live trading. The stock’s ascent pushes it to the 52-week high, supported by heavy volume across 34.66 million shares and an intraday peak reaching ₹320.